Capricor Therapeutics (NASDAQ:CAPR) CFO Sells $753,250.00 in Stock

Capricor Therapeutics, Inc. (NASDAQ:CAPR) CFO Anthony Bergmann sold 25,000 shares of Capricor Therapeutics stock in a transaction dated Tuesday, March 31st. The stock was sold at an average price of $30.13, for a total value of $753,250.00. Following the sale, the chief financial officer directly owned 8,223 shares in the company, valued at approximately $247,758.99. The trade was a 75.25% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Capricor Therapeutics Stock Performance

Shares of CAPR opened at $32.11 on Friday. Capricor Therapeutics, Inc. has a one year low of $4.30 and a one year high of $40.37. The stock has a 50-day moving average price of $27.38 and a 200 day moving average price of $19.10. The company has a market capitalization of $1.85 billion, a P/E ratio of -14.21 and a beta of 0.48.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings data on Thursday, March 12th. The biotechnology company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.11). As a group, equities research analysts forecast that Capricor Therapeutics, Inc. will post -1.21 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Capricor Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Creek Drive Management Group LLC acquired a new position in Capricor Therapeutics in the fourth quarter worth $1,039,000. SB Capital Management Inc acquired a new stake in shares of Capricor Therapeutics during the fourth quarter worth $11,544,000. Ikarian Capital LLC lifted its position in shares of Capricor Therapeutics by 118.4% in the 4th quarter. Ikarian Capital LLC now owns 578,015 shares of the biotechnology company’s stock worth $16,682,000 after buying an additional 313,373 shares during the last quarter. Virtus Investment Advisers LLC lifted its position in shares of Capricor Therapeutics by 25.2% in the 4th quarter. Virtus Investment Advisers LLC now owns 10,224 shares of the biotechnology company’s stock worth $295,000 after buying an additional 2,061 shares during the last quarter. Finally, Susquehanna Portfolio Strategies LLC acquired a new position in shares of Capricor Therapeutics in the 4th quarter valued at about $384,000. 21.68% of the stock is currently owned by institutional investors.

More Capricor Therapeutics News

Here are the key news stories impacting Capricor Therapeutics this week:

• Positive Sentiment: Several brokerages have raised targets or issued overweight/buy ratings (Cantor Fitzgerald $62, Piper Sandler $58, Maxim $50), supporting upside expectations versus the consensus.
• Neutral Sentiment: One director sale (7,529 shares at $32.00) was executed under a pre‑arranged Rule 10b5‑1 plan, which typically mutes the negative signal from insider selling but does not eliminate market concern. SEC Filing
• Neutral Sentiment: Institutional ownership is modest (~21.7%) with a few small new positions reported — indicates some institutional interest but not large-scale conviction yet. Institutional Holdings
• Negative Sentiment: CFO Anthony Bergmann sold 25,000 shares on March 31 at an average $30.13 (disclosed in an SEC Form 4), reducing his direct holding by ~75% — a sizable insider reduction that may worry investors about near-term outlook or personal liquidity needs. CFO Sale Filing
• Negative Sentiment: Director Karimah Es Sabar sold large blocks across March 31–April 1–2 (61,265 @ $30.17; 53,735 @ $31.03; plus a 7,529 @ $32.00 sale under a 10b5‑1 plan). Combined insider disposals this week total roughly 148k shares for several million dollars — a significant decrease in insider ownership that can pressure sentiment. Director Sale Filing
• Negative Sentiment: Capricor missed Q4 EPS estimates (reported -$0.62 vs. consensus -$0.51 on March 12), which is a near-term fundamental negative that analysts and investors will weigh against bullish price targets. Earnings Report

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. HC Wainwright reiterated a “buy” rating and set a $60.00 price objective on shares of Capricor Therapeutics in a research note on Tuesday, March 10th. Piper Sandler reissued an “overweight” rating and issued a $58.00 target price (up from $45.00) on shares of Capricor Therapeutics in a research report on Friday, March 13th. Wall Street Zen lowered shares of Capricor Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, January 11th. B. Riley Financial increased their price target on shares of Capricor Therapeutics from $50.00 to $63.00 and gave the stock a “buy” rating in a research report on Friday, March 13th. Finally, UBS Group set a $50.00 price target on Capricor Therapeutics in a research note on Monday, December 15th. Nine research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $46.09.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.